This year’s biotech laggards primed for 2026 recovery, says Goldman Sachs’ Richter

December 19, 2025 admin

• Facebook
• Twitter
• Pinterest

CNBC TelevisionFri, December 19, 2025 10:42pmURL:
Embed:

CNBC’s “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.

• Facebook
• Twitter
• Pinterest

Related posts

• 

  May 9, 2026 admin 0

  VA Rep. McClellan seeks to ban partisan gerrymandering #shorts #politics #virginia

  Bloomberg TelevisionSat, May 9, 2026 4:43amURL:Embed:Virginia Rep. Jennifer McClellan joins Kailey Leinz to discuss the US...

  Business 

• 

  May 9, 2026 admin 0

  US Awaits Iranian Response as Clashes Raise Tensions | Balance of Power 05/08/2026

  Bloomberg TelevisionSat, May 9, 2026 4:43amURL:Embed:“Balance of Power: Late Edition” focuses on the intersection of politics...

  Business 

• 

  May 9, 2026 admin 0

  Nintendo ”sincerely apologizes” for raising Switch 2 prices to $499. 💸

  Yahoo FinanceSat, May 9, 2026 4:43amURL:Embed:Nintendo ”sincerely apologizes” for raising Switch 2 prices to $499. 💸

  Business